Avijit Majumder

Avijit Majumder

Director Director DIN 07821832
DIN 07821832 First appointment May 2017 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2017
Shareholding value β€’β€’β€’β€’ Premium profile

About Avijit Majumder

Data last updated:

Avijit Majumder was a Director at Medright Biogenics Private Limited (2017) and Director at Roll Bonkers Private Limited (from 2017). The companies operate in Chemicals.

DIN 07821832
Primary Designation Director
Industry Chemicals
First Appointment 29 May 2017
Oldest Company Age 9 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Medright Biogenics Private Limited U24100WB2017PTC221242
Director29 May 20172017₹48.5 Lakh (FY 2024)Active
Roll Bonkers Private Limited U15127WB2017PTC221404
Director07 Jun 20172017Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Roll Bonkers Private Limited
Medright Biogenics Private Limited
Premium access

Shareholding and investment profile for Avijit Majumder

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Avijit Majumder

Avijit Majumder was first appointed on 29 May 2017 as Director at Medright Biogenics Private Limited.

Avijit Majumder held 2 earlier board appointments: Medright Biogenics Private Limited (Director, 29 May 2017 to 30 Dec 2017); Roll Bonkers Private Limited (Director, from 07 Jun 2017).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available